185 related articles for article (PubMed ID: 18473793)
1. STAT 3 as a target for cancer drug discovery.
Costantino L; Barlocco D
Curr Med Chem; 2008; 15(9):834-43. PubMed ID: 18473793
[TBL] [Abstract][Full Text] [Related]
2. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
3. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
4. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.
Debnath B; Xu S; Neamati N
J Med Chem; 2012 Aug; 55(15):6645-68. PubMed ID: 22650325
[No Abstract] [Full Text] [Related]
6. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
7. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
Haftchenary S; Avadisian M; Gunning PT
Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
[TBL] [Abstract][Full Text] [Related]
10. Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
Cerulli RA; Shehaj L; Tosic I; Jiang K; Wang J; Frank DA; Kritzer JA
Bioorg Med Chem; 2020 Jun; 28(12):115542. PubMed ID: 32503696
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription 3 inhibitors: a patent review.
Page BD; Ball DP; Gunning PT
Expert Opin Ther Pat; 2011 Jan; 21(1):65-83. PubMed ID: 21114420
[TBL] [Abstract][Full Text] [Related]
12. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
Page BD; Fletcher S; Yue P; Li Z; Zhang X; Sharmeen S; Datti A; Wrana JL; Trudel S; Schimmer AD; Turkson J; Gunning PT
Bioorg Med Chem Lett; 2011 Sep; 21(18):5605-9. PubMed ID: 21788134
[TBL] [Abstract][Full Text] [Related]
13. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.
Schust J; Sperl B; Hollis A; Mayer TU; Berg T
Chem Biol; 2006 Nov; 13(11):1235-42. PubMed ID: 17114005
[TBL] [Abstract][Full Text] [Related]
14. STAT-3 inhibitors: state of the art and new horizons for cancer treatment.
Lavecchia A; Di Giovanni C; Novellino E
Curr Med Chem; 2011; 18(16):2359-75. PubMed ID: 21568920
[TBL] [Abstract][Full Text] [Related]
15. Chemical probes that competitively and selectively inhibit Stat3 activation.
Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
[TBL] [Abstract][Full Text] [Related]
16. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
Furtek SL; Matheson CJ; Backos DS; Reigan P
Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
[TBL] [Abstract][Full Text] [Related]
18. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.
Masciocchi D; Gelain A; Villa S; Meneghetti F; Barlocco D
Future Med Chem; 2011 Apr; 3(5):567-97. PubMed ID: 21526897
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
20. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.
Groner B; Weber A; Mack L
Bioengineered; 2012; 3(6):320-5. PubMed ID: 22825353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
